<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00524017</url>
  </required_header>
  <id_info>
    <org_study_id>J0644 CDR0000562250</org_study_id>
    <secondary_id>P50CA096784</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0644</secondary_id>
    <secondary_id>JHOC-NA_00001757</secondary_id>
    <nct_id>NCT00524017</nct_id>
  </id_info>
  <brief_title>Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract</brief_title>
  <official_title>Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as cetuximab, can block abnormal cell growth in&#xD;
      different ways. Some block the ability of abnormal cells to grow and spread. Others find&#xD;
      abnormal cells and help kill them or carry cell-killing substances to them.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well cetuximab works in treating&#xD;
      patients with precancerous lesions of the upper aerodigestive tract.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the histologic response rate in patients with high-risk, premalignant&#xD;
           lesions of the upper aerodigestive tract treated with cetuximab.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the clinical response rate in these patients.&#xD;
&#xD;
        -  To determine if patterns of epidermal growth factor receptor (EGFR) component expression&#xD;
           are altered in these patients.&#xD;
&#xD;
        -  To determine the change in status of genetic alterations, including loss of&#xD;
           heterozygosity, in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified by lesion type [diffuse&#xD;
      dysplasia vs recurrent dysplasia vs dysplastic lesions with 3p or 9p loss of heterozygosity&#xD;
      (LOH)]. Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
        -  Arm I (treatment): Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22,&#xD;
           29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II (control): Patients receive regular follow-up care. Patients have the option of&#xD;
           receiving cetuximab after completion of the study.&#xD;
&#xD;
      In both arms, patients with persistent or recurrent high-grade dysplasia or dysplastic&#xD;
      lesions with 3p or 9p LOH undergo surgical resection, if feasible, after week 8.&#xD;
&#xD;
      Tumor biopsy samples are obtained at baseline* and after week 8 for histologic and biomarker&#xD;
      correlative studies. Tissue samples are analyzed by histopathology to determine histologic&#xD;
      changes in post-treatment lesions and by immuno-histochemistry (IHC) to measure expression&#xD;
      and activation of EGFR signaling pathway components. LOH studies are also performed.&#xD;
&#xD;
      NOTE: *Paraffin-embedded tissue from the original diagnostic biopsy may be used for baseline&#xD;
      assessment, if the diagnostic biopsy was performed within 3 months prior to study entry.&#xD;
&#xD;
      After completion of study therapy, patients are followed at approximately 1 month, every 3&#xD;
      months for 2 years, and then every 6 months for up to 5 years as per routine standard of&#xD;
      care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Objective Response Based on Histologic Grade</measure>
    <time_frame>8 weeks</time_frame>
    <description>Histologic downgrade by at least one grade of dysplasia (e.g Severe to Moderate).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Objective Response Based on Clinical Assessment</measure>
    <time_frame>8 weeks</time_frame>
    <description>Clinical visualization on whether lesion responded to treatment (i.e., direct visualization of the lesion combined with histologic grade)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of Epidermal Growth Factor Receptor (EGFR) Pathway Components and Molecular Alterations in Pre-treatment Biopsies</measure>
    <time_frame>Baseline (pre-treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of EGFR Pathway Components and Molecular Alterations in Post-treatment Biopsies</measure>
    <time_frame>At 8 weeks post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Up to year 5 years post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Recurrence</measure>
    <time_frame>Up to year 5 years post-treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Arm I (treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (control)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receive regular follow-up care</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>given IV</description>
    <arm_group_label>Arm I (treatment)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed high-risk, premalignant lesions of the upper aerodigestive&#xD;
             tract, meeting one of the following criteria:&#xD;
&#xD;
               -  Unresectable, diffuse high-grade dysplasia, defined as moderate or severe&#xD;
                  dysplasia that is not assessable by physical examination and/or that cannot be&#xD;
                  excised by standard surgical techniques&#xD;
&#xD;
               -  previously treated HNSCC with persistent or recurrent high grade dysplasia with&#xD;
                  no evidence of head and neck malignancy for three months prior to enrollment or&#xD;
                  who have successfully completed therapy for head and neck malignancy more than 3&#xD;
                  months prior to enrollment.&#xD;
&#xD;
               -  Dysplastic lesions with 3p or 9p loss of heterozygosity&#xD;
&#xD;
          -  Disease location amenable to endoscopic biopsy in an outpatient clinical setting or&#xD;
             operative biopsy within the routine scheduling and practice of clinical care&#xD;
&#xD;
               -  No medical contraindication to biopsy of the target lesion&#xD;
&#xD;
               -  Pathology must be reviewed by the Johns Hopkins Hospital Department of Pathology&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt; 1,000/mm³&#xD;
&#xD;
          -  Platelet count &gt; 75,000/mm³&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
          -  Total serum bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after&#xD;
             completion of study therapy&#xD;
&#xD;
          -  No concurrent illness likely to preclude study therapy or surgical resection&#xD;
&#xD;
          -  Patients with a history of a curatively treated malignancy are eligible provided they&#xD;
             are disease-free and have a survival prognosis that exceeds 5 years&#xD;
&#xD;
          -  No evidence of clinically active interstitial lung disease&#xD;
&#xD;
               -  Patients with chronic, stable radiographic changes who are asymptomatic are&#xD;
                  eligible&#xD;
&#xD;
          -  No history or radiological evidence of pulmonary fibrosis&#xD;
&#xD;
          -  No acute myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No uncontrolled angina, arrhythmia, or congestive heart failure&#xD;
&#xD;
          -  No evidence of other severe or uncontrolled systemic disease (e.g., unstable or&#xD;
             uncompensated respiratory, cardiac, hepatic, or renal disease)&#xD;
&#xD;
          -  No evidence of any other significant clinical disorder or laboratory finding that&#xD;
             would preclude study participation&#xD;
&#xD;
          -  No known severe hypersensitivity to cetuximab or any of its excipients&#xD;
&#xD;
          -  No prior hypersensitivity reaction to chimerized or murine monoclonal antibody therapy&#xD;
&#xD;
          -  No severe abnormality of the cornea&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior oncologic or other major surgery or biopsy&#xD;
&#xD;
          -  More than 30 days since prior non-approved or investigational drugs&#xD;
&#xD;
          -  No prior chemotherapy, radiotherapy, or surgery for the premalignant lesions&#xD;
&#xD;
          -  No prior EGFR-targeted agents (e.g., cetuximab, gefitinib, or erlotinib)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Califano, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucille P. Markey Cancer Center at University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenebaum Cancer Center at University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Cancer Institute at New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Centers</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hollings Cancer Center at Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 31, 2007</study_first_submitted>
  <study_first_submitted_qc>August 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2007</study_first_posted>
  <results_first_submitted>February 13, 2020</results_first_submitted>
  <results_first_submitted_qc>February 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 12, 2020</results_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypopharyngeal cancer</keyword>
  <keyword>laryngeal cancer</keyword>
  <keyword>lip and oral cavity cancer</keyword>
  <keyword>nasopharyngeal cancer</keyword>
  <keyword>oropharyngeal cancer</keyword>
  <keyword>paranasal sinus and nasal cavity cancer</keyword>
  <keyword>salivary gland cancer</keyword>
  <keyword>precancerous condition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study enrolled patients with premalignant lesions of the Head and Neck with mild, moderate or severe dysplasias</recruitment_details>
      <pre_assignment_details>16 participants did not have biopsy proven dysplasia as required by protocol and were not randomized to treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Treatment)</title>
          <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.&#xD;
cetuximab: given IV</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Control)</title>
          <description>Patients receive regular follow-up care</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Treatment)</title>
          <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.&#xD;
cetuximab: given IV</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Control)</title>
          <description>Patients receive regular follow-up care</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Objective Response Based on Histologic Grade</title>
        <description>Histologic downgrade by at least one grade of dysplasia (e.g Severe to Moderate).</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Treatment)</title>
            <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.&#xD;
cetuximab: given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Control)</title>
            <description>Patients receive regular follow-up care</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Objective Response Based on Histologic Grade</title>
          <description>Histologic downgrade by at least one grade of dysplasia (e.g Severe to Moderate).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Objective Response Based on Clinical Assessment</title>
        <description>Clinical visualization on whether lesion responded to treatment (i.e., direct visualization of the lesion combined with histologic grade)</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Treatment)</title>
            <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.&#xD;
cetuximab: given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Control)</title>
            <description>Patients receive regular follow-up care</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Objective Response Based on Clinical Assessment</title>
          <description>Clinical visualization on whether lesion responded to treatment (i.e., direct visualization of the lesion combined with histologic grade)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Status of Epidermal Growth Factor Receptor (EGFR) Pathway Components and Molecular Alterations in Pre-treatment Biopsies</title>
        <time_frame>Baseline (pre-treatment)</time_frame>
        <population>Data was not collected for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Treatment)</title>
            <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.&#xD;
cetuximab: given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Control)</title>
            <description>Patients receive regular follow-up care</description>
          </group>
        </group_list>
        <measure>
          <title>Status of Epidermal Growth Factor Receptor (EGFR) Pathway Components and Molecular Alterations in Pre-treatment Biopsies</title>
          <population>Data was not collected for this outcome</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Status of EGFR Pathway Components and Molecular Alterations in Post-treatment Biopsies</title>
        <time_frame>At 8 weeks post-treatment</time_frame>
        <population>Data was not collected for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Treatment)</title>
            <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.&#xD;
cetuximab: given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Control)</title>
            <description>Patients receive regular follow-up care</description>
          </group>
        </group_list>
        <measure>
          <title>Status of EGFR Pathway Components and Molecular Alterations in Post-treatment Biopsies</title>
          <population>Data was not collected for this outcome</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival</title>
        <time_frame>Up to year 5 years post-treatment</time_frame>
        <population>No patients were followed for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Treatment)</title>
            <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.&#xD;
cetuximab: given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Control)</title>
            <description>Patients receive regular follow-up care</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <population>No patients were followed for this outcome measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Recurrence</title>
        <time_frame>Up to year 5 years post-treatment</time_frame>
        <population>No patients were followed for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Treatment)</title>
            <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.&#xD;
cetuximab: given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Control)</title>
            <description>Patients receive regular follow-up care</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Recurrence</title>
          <population>No patients were followed for this outcome measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Treatment)</title>
          <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.&#xD;
cetuximab: given IV</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Control)</title>
          <description>Patients receive regular follow-up care</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Zubair Khan</name_or_title>
      <organization>SKCCC</organization>
      <phone>4109553157</phone>
      <email>zkhan@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

